Published: 01 August 2024
Summary
Life science organizations are deepening their engagement with generative AI technologies, according to June 2024 Gartner research. These insights offer benchmarking and trends to help CIOs navigate the evolving landscape, track adoption progression and prioritize strategic initiatives effectively.
Included in Full Research
Overview
Key Findings
Generative AI (GenAI) is rapidly being integrated into the life science value chain, with implementation surging in scientific research and drug discovery, commercialization, clinical development, manufacturing and supply chain.
Fifteen percent of respondents report having 11 or more GenAI use cases in production and are in an ideal position to steer the industry’s direction. However, significant industry challenges remain, as indicated by respondents who do not have any use cases in production.
A significant number of respondents rank procuring GenAI solutions from enterprise software vendors as their primary strategy.
Life science organizations face a myriad of challenges, such as
Clients can log in to view the entire
document.